EP0845979A1 - Cosmetic method for treating and preventing the signs of skin ageing - Google Patents

Cosmetic method for treating and preventing the signs of skin ageing

Info

Publication number
EP0845979A1
EP0845979A1 EP97922001A EP97922001A EP0845979A1 EP 0845979 A1 EP0845979 A1 EP 0845979A1 EP 97922001 A EP97922001 A EP 97922001A EP 97922001 A EP97922001 A EP 97922001A EP 0845979 A1 EP0845979 A1 EP 0845979A1
Authority
EP
European Patent Office
Prior art keywords
retinoid
composition
skin
mentioned
retinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97922001A
Other languages
German (de)
English (en)
French (fr)
Inventor
Dominique Castelli
Gerd Ries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roc SA
Original Assignee
Roc SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roc SA filed Critical Roc SA
Publication of EP0845979A1 publication Critical patent/EP0845979A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to the treatment of the skin using compositions containing retmoids, in order to combat skin ageing and the formation of wrinkles More particularly, the invention relates to a method for the cosmetic treatment of the skin, m particular the face, the neck or the hands, with retinoid compositions, which is less irritant than the known methods and allows the individual to use higher and more effective doses during the treatment, and at an earlier stage than previously
  • patent US-5,401,517 suggests using a lower dose of retmoids for several days and then increasing the dose of retmoids in the composition on the following days, when the sk has become accustomed to the compounds.
  • this method has drawbacks since it requires a change in the application regime to use a different formulation containing a higher dose of retinoid. This places the onus on the user to remember to change product and to buy an additional product before the first one has been used up.
  • compositions containing low doses of retmoids are used during the day but allow the individual to apply formulations containing a higher, more effective dose in the evening before going to bed. All of each tube of product will be used during the treatment, thus avoiding any loss of product and excessive costs.
  • the application procedure will remain similar from the initial day of the treatment, which will thereby encourage the individual to acquire suitable habits and to maintain these habits from the first day of use.
  • the individual applies high doses of retinoids from the start of the treatment and thus obtains the benefits of high doses immediately.
  • one of the subjects of the inven ⁇ tion is to provide a method for treating the skin by applying an effective amount of retinoid onto the skin during the day, in order to combat the ageing process.
  • Another of the subjects of the invention is to provide a method for treating the skin with retinoids and for attenuating the irritation produced by retinoids.
  • Another of the subjects of the invention is to provide a method for treating the skin which allows a high dose of retinoids to be applied from the first day of use .
  • Another subject of the invention is to provide a method for treating the skin which allows the individual to use the retinoid-based product on a daily basis from the start of the treatment.
  • the invention relates to a method for treating the skin according to the following procedure : a) application of a composition containing a weak dose of retinoids, comprising a compound of retinoid type which is effective for combating skin ageing, at a sub-irritant dose, once a day; and b) application of a composition containing a higher dose of retinoids approximately 10 to 16 hours, advantageously 12 hours, after the first dose.
  • composition formulated specifi- cally for a part of the face for example the eyes, may be applied once or twice a day at a low, sub-irritant dose.
  • the formulations serving as vehicle for each of the applications of the product in the method according to the invention may be identical or may be different, depending upon the particular requirements of the regime and of the user.
  • a base or a lighter formulation may be used during the day whilst a richer emulsion of firmer consistency may be used at night for greater skin comfort while the individual is resting.
  • the aim pursued in developing the invention is to allow the individual using retinoid-based compositions to become more tolerant to retinoids more quickly. Often, individuals react by developing red ⁇ ness, itchiness, stinging, a burning sensation and desquamation when retinoids are applied. However, by using retinoids in an application procedure according to the present invention, the individuals may tolerate the application of retinoids at an effective dose more quickly then if an amount which produces the irritation had to be applied immediately on a daily basis.
  • retinoids should be understood to include retinoic acid or tretinoin, retinol, retinaldehydes and salts and esters thereof.
  • Typical salts are alkali metal, ammonium and C 2 -C 30 ammonium salts.
  • the sodium, potassium, triethanolammonium and ammonium salts are particularly preferred. Combinations of all the above compounds may be present in the compositions.
  • retinol and retinoic acid should be understood to include hydrogenated and non-hydrogenated isomers such as 9-cis-retinol, didehydroretinol, 13-cis- retinoic acid, 13-trans-retinoic acid and didehydro- retinoic acid.
  • Other retinoids which are effective in treating skin ageing, wrinkles and other anomalies are present in US patents Nos. 4,603,146, 4,887,805 and 4,888,342, the contents of which are incorporated herein by way of reference . They may be present in the compositions used according to the invention at concen ⁇ trations from about 0.0001 % to about 5 %.
  • they will be present in amounts of between 0.0001 % and about 0.3 %. Even more preferably, they must be present in amounts of between about 0.01 % and about 0.075 %. Even more preferably, they are present in amounts of between about 0.015 % and about 0.04 %.
  • the concentrations will be determined by those skilled in the art according to the nature of the retinoids specifically present in the composition. They will also be adapted as a function of the excipients and of the ability of the formulation to release active retinoid molecules which can be used by the skin. A large variety of pharmaceutically and/or cosmetologically acceptable supports may be used for the present invention.
  • the amounts of vehicles may be from about 1 to 99.9 % and preferably from about 80 to 98 %, advantageously between about 95 and about 99.950 % of the composition by weight.
  • compositions used in the products according to the invention as vehicles or bases may be in the form of emulsions, such as oil-in-water or water-in-oil emulsions. They may also be in the form of liposomal emulsions or any other emulsion known to those skilled in the art, which are physically and chemically stable.
  • the compositions which may be used in the method according to the invention comprise water-in-oil emulsions as described in EP 91 9137059 which is incorporated herein by way of reference.
  • Oil-in-water formulations which may be used in the method according to the invention are presented in WO/US 95/11750 which is incorporated herein by way of reference .
  • Liposomal compositions wnich may be used as vehicles for the retinoid compositions in the method according to the invention are described in WO/US 96/04557 which is incorporated herein by way of reference.
  • compositions may also be formulated in gel or lotion form with cosmetologically acceptable excipients known to those skilled in the art.
  • compositions according to the invention may also be included in the compositions according to the invention.
  • ingredients may include, in parti- cular, sunscreens and screening agents, tanning agents, antiacne agents, in particular salicylic acid, antiinflammatories (in particular panthenol, Gingko biloba, glycyrrhetinic acid, etc.) , depigmenting agents, hydrating agents, plant extracts and other anti-wrinkle agents.
  • the sunscreens comprise, in particular, 4-aminobenzoic acid and derivatives thereof, dibenzoyl- methane, camphor derivatives, homosalate, oxybenzone, cinnamic esters, 3-imidazol-4-ylacrylic acid and benz- imidazole derivatives such as 2-phenylbenzimidazole- 5-sulphonic acid and its sodium and TEA salts.
  • the first application of the day should be made in the morning, after cleansing the skin, on waking up.
  • the first application should contain a sub-irritant dose of retinoids, for example from about 0.0001 % to about 0.04 % and preferably less than 0.04 %, advantageously from 0.01 % to 0.02 %.
  • a particularly suitable concentration is 0.015 % by weight.
  • the first application may preferably be made in an oil-in-water emulsion which is relatively light and easy to apply and to wear.
  • the second application should preferably be made in the evening, just before going to bed and approximately 10 to 16 hours after the first applica ⁇ tion.
  • the second application should contain a relatively large amount of retinoids, which will allow the administration of a larger amount of retinoids onto the skin.
  • This higher-concentration formulation will be more effective as a remedy for skin anomalies, since it contains a higher dose of active principles.
  • This second application may be made in an oil-in-water emulsion. However, it may also be placed in a water-in- oil emulsion. Water-in-oil emulsions have a tendency to be slightly more nourishing and "greasy" than oil-in- water compositions. However, such formulations may be well tolerated at night and provide the skin with complementary moisturization.
  • the retinoid content in the second application should preferably be from about 0.04 % to 0.3 %, although it may be higher if the patient is capable of tolerating this dosage.
  • compositions specially formulated for particular areas of the upper part of the body such as the neck and around the eyes or the mouth, may be used in lower retinoid doses along with other formulations in order to provide additional assistance to these areas without causing any further irritation.
  • the examples which follow are intended to illustrate the present invention without limiting its scope in any way.
  • EXAMPLE 1 A composition containing retinol, having the formulation A and containing 0.015 % by weight of retinol, is applied daily to the face and the neck in the morning after cleansing the appropriate areas. In the evening, the neck and the face are again cleansed and a retinol formulation, having the composition B and containing 0.075 % by weight of retinol, is applied to the same area. The irritation symptoms are expected to be less than if a formulation containing about 0.04 % retinol was applied twice a day.
  • the tolerance results are compared after treat ⁇ ment for 15 days and 1 month in 2 groups of users, according to two different administration procedures.
  • the 1st group applies formulation A in the morning and formulation B in the evening as indicated above.
  • a second group applies formulation C in the morning and formulation D in the evening under the same conditions.
  • the tolerance is better in the 1st group, where less than 4 % of the individuals stop the application after 15 days.
  • formulation A in the morning thus entails virtually no additional irritation but allows the skin to be prepared to receive the dose present in formulation B and to adjust the total daily dose administered.
  • formulation E in the morning may thus be combined with that of a stronger-dosed formulation, such as formulation B, in the evening, onto the entire face.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP97922001A 1996-06-07 1997-06-05 Cosmetic method for treating and preventing the signs of skin ageing Withdrawn EP0845979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9607110 1996-06-07
FR9607110A FR2749511B1 (fr) 1996-06-07 1996-06-07 Methode cosmetique de traitement et de prevention des signes du vieillissement de la peau
PCT/IB1997/000642 WO1997046221A1 (en) 1996-06-07 1997-06-05 Cosmetic method for treating and preventing the signs of skin ageing

Publications (1)

Publication Number Publication Date
EP0845979A1 true EP0845979A1 (en) 1998-06-10

Family

ID=9492845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97922001A Withdrawn EP0845979A1 (en) 1996-06-07 1997-06-05 Cosmetic method for treating and preventing the signs of skin ageing

Country Status (13)

Country Link
EP (1) EP0845979A1 (xx)
JP (1) JPH11510824A (xx)
KR (1) KR19990036233A (xx)
CN (1) CN1198092A (xx)
AU (1) AU2786197A (xx)
BR (1) BR9702284A (xx)
CA (1) CA2228750A1 (xx)
CZ (1) CZ31798A3 (xx)
EA (1) EA199800194A1 (xx)
FR (1) FR2749511B1 (xx)
HU (1) HUP9802916A3 (xx)
PL (1) PL324929A1 (xx)
WO (1) WO1997046221A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017549A (en) * 1997-09-30 2000-01-25 E-L Management Corp. Non-irritating cosmetic and pharmaceutical compositions
KR100404868B1 (ko) * 2000-03-28 2003-11-15 김삼 안정한 레티놀 팔미테이트 및 그를 함유하는 화장료 조성물
FR2817475B1 (fr) * 2000-12-04 2005-06-17 Rocher Yves Biolog Vegetale Utilisation d'une association proteases-source de retinol pour s'opposer au vieillissement cutane
EP1458346A2 (en) * 2001-12-20 2004-09-22 Johnson & Johnson Consumer France SAS Compositions containing a retinoid and malt extract
US20050019356A1 (en) * 2003-07-25 2005-01-27 The Procter & Gamble Company Regulation of mammalian keratinous tissue using N-acyl amino acid compositions
US9387160B2 (en) * 2008-12-22 2016-07-12 Johnson & Johnson Consumer Holdings France Composition and method of treating skin conditions
JP2013056867A (ja) * 2011-09-09 2013-03-28 Pias Arise Kk 概日リズム調整用キット及び概日リズムの調整方法
US10639252B2 (en) * 2011-09-23 2020-05-05 Allergan, Inc. Compositions for skin exfoliation and use thereof
FR3006191B1 (fr) * 2013-06-03 2016-04-29 Pierre Fabre Dermo-Cosmetique Compositions cosmetiques ou dermatologiques associant du retinaldehyde et de l'oleamide de glycylglycine, et leurs utilisations en cosmetique ou dermatologie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052282B (it) * 1967-10-25 1981-06-20 Johnson & Johnson Composizione per la cura dell acne
US5401517A (en) * 1993-11-15 1995-03-28 Elizabeth Arden Company, Division Of Conopco, Inc. Cosmetic method for treatment of skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9746221A1 *

Also Published As

Publication number Publication date
JPH11510824A (ja) 1999-09-21
BR9702284A (pt) 1999-12-28
CN1198092A (zh) 1998-11-04
FR2749511B1 (fr) 1998-08-28
FR2749511A1 (fr) 1997-12-12
HUP9802916A3 (en) 1999-08-30
HUP9802916A2 (hu) 1999-03-29
AU2786197A (en) 1998-01-05
KR19990036233A (ko) 1999-05-25
PL324929A1 (en) 1998-06-22
WO1997046221A1 (en) 1997-12-11
EA199800194A1 (ru) 1998-08-27
CZ31798A3 (cs) 1998-06-17
CA2228750A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
AU639063B2 (en) Skin care compositions
EP0989846B1 (en) Non-irritating cosmetic and pharmaceutical compositions
US6955816B2 (en) Anti-aging skin care composition and uses thereof
JPH1087476A (ja) ヒドロキシ酸またはレチノイドを含有する組成物中の刺激防止剤としてのルリヂサ種子油
WO1996014085A1 (fr) Preparation dermoprotectrice d'usage externe
EP0687467A2 (de) Wirkstoffkombinationen mit einem Gehalt and Glyceylalkylethern und kosmetische und dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
EP1216696A2 (en) Method for reducing the appearance of dark circles under the eyes
US7655255B2 (en) Topical composition for transdermal administration
JP2937446B2 (ja) 白髪防止黒化剤
US20220183951A1 (en) Skin treatment methods and compositions with retinoid and delivery systems thereof
US20190151214A1 (en) Methods and compositions for treatment of skin
EP0845979A1 (en) Cosmetic method for treating and preventing the signs of skin ageing
EP1192939A2 (en) Methods for reduction of inflammation and erythema
EP1219288A2 (en) Treatment for skin
EP1192940A1 (en) Compositions and methods for promoting clear skin using an alkanolamine
US20050019354A1 (en) Topical benfotiamine treatments
JPH11302133A (ja) 頭皮頭髪用化粧料
JPH10273424A (ja) 頭髪用化粧料
JPH10273422A (ja) 頭髪用化粧料
AU2006201889A1 (en) Treatment for skin
AU2004242563A1 (en) Method for promoting clear skin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 980302

17P Request for examination filed

Effective date: 19980525

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20000221